Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.40 per share
-
Shares outstanding
-
23.6M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
379K
-
Shares change
-
+184K
-
Total reported value, excl. options
-
$2.48M
-
Value change
-
+$1.19M
-
Number of buys
-
2
-
Price
-
$6.44
Significant Holders of Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) as of Q4 2023
3 filings reported holding AUTL - Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share as of Q4 2023.
Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 379K shares
of 23.6M outstanding shares and own 1.61% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (21.3M shares), Blackstone Inc. (20.5M shares), Paradigm Biocapital Advisors LP (12.6M shares), Deep Track Capital, LP (11.9M shares), TFG Asset Management GP Ltd (8M shares), Cormorant Asset Management, LP (5.45M shares), ARMISTICE CAPITAL, LLC (3.85M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.83M shares), Frazier Life Sciences Management, L.P. (3.75M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (3M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.